RT Journal Article
SR Electronic
T1 Common and rare genetic variation intersects with ancestry to influence human skin and plasma carotenoid concentrations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.20.24319465
DO 10.1101/2024.12.20.24319465
A1 Han, Yixing
A1 Mwesigwa, Savannah
A1 Wu, Qiang
A1 Laska, Melissa N.
A1 Jilcott Pitts, Stephanie B.
A1 Moran, Nancy E.
A1 Hanchard, Neil A.
YR 2024
UL http://medrxiv.org/content/early/2024/12/23/2024.12.20.24319465.abstract
AB Carotenoids are dietary bioactive compounds with health effects that are biomarkers of fruit and vegetable intake. Here, we examine genetic associations with plasma and skin carotenoid concentrations in two rigorously phenotyped human cohorts (n=317). Analysis of genome-wide SNPs revealed heritability to vary by genetic ancestry (h²=0.08–0.44) with ten SNPs at four loci reaching genome-wide significance (P<5E-08) in multivariate models, including at RAPGEF1 (rs3765544, P=8.86E-10, beta=0.75) with α-carotene, and near IGSF11 (rs80316816, P=6.25E-10, beta=0.74), with cryptoxanthin; these were replicated in the second cohort (n=110). Multiple SNPs near IGSF11 demonstrated genotype-dependent dietary effects on plasma cryptoxanthin. Deep sequencing of 35 candidate genes revealed associations between the PKD1L2-BCO1 locus and plasma β-carotene (Padj=0.04, beta=-1.3 to -0.3), and rare, ancestry-restricted, damaging variants in CETP (rs2303790) and APOA1 (rs756535387) in individuals with high skin carotenoids. Our findings implicate novel loci in carotenoid disposition and indicate the importance of including cohorts of diverse genetic ancestry.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04056624Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04056624 Funding StatementThis research was supported by the NIH NHLBI (SJP, MNL, NEM, QW: 1R01HL142544-01A1), by funding from NIH NHGRI (HG-200412 to N.A.H.), and the USDA/ARS (cooperative agreement 3092-51000-059-002S to NEM). The work and views expressed do not reflect the views of the NIH or the USDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee IRB# UMCIRB 17-001242 of East Carolina University (ECU) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://h3africa.org/index.php/2019/12/12/h3africa-chip-faq/ https://www.illumina.com/content/infinium-h3africa-consortium-array-data-sheet) https://www.internationalgenome.org/